The association between mupirocin use and plasmid-based high-level resistance development mediated through mupA in CoNS has not been quantified. We determined acquisition of mupirocin resistance in Staphylococcus aureus and CoNS in surgery patients treated peri-operatively with mupirocin.
Introduction
Mupirocin is a topical antibiotic and the cornerstone of decolonization regimens for MSSA and MRSA in patients and healthcare personnel. Peri-operative eradication of Staphylococcus aureus nasal carriage, with mupirocin and chlorhexidine body washings, reduces the incidence of post-operative S. aureus infections by 58%. 1 However, the rapid identification of S. aureus carriers and immediate application of treatment is logistically challenging and costly. Therefore, universal peri-operative decolonization, irrespective of S. aureus carrier status, would be more cost-effective. 2 Yet, extensive use of mupirocin, as in universal decolonization, may facilitate emergence of mupirocin resistance in S. aureus and CoNS, but this risk has not been quantified. We therefore investigated the effects of universal decolonization with topical mupirocin and chlorhexidine body washings on resistance in CoNS and S. aureus.
Patients and methods

Setting and patient population
This study was performed at a tertiary teaching hospital in Utrecht, The Netherlands. A universal decolonization strategy was implemented on three surgical wards: a cardiothoracic surgery ward, an orthopaedic surgery ward and a neurosurgical ward for all patients undergoing surgery with an expected stay of ≥4 days, using mupirocin nasal ointment three times daily for 5 days and chlorhexidine body washings once daily for 5 days, starting decolonization on the day of admission. On the three surgical wards, nasal swabs for detection of mupirocin-resistant staphylococci were taken from all consecutive patients treated with mupirocin, between June 2012 and June 2013, before the start of decolonization treatment (T1) and 4 days after surgery (1 day after completing decolonization treatment) (T2). A nasal swab was also obtained if patients were discharged or transferred to another hospital before completing the 5 days of decolonization therapy. Patients able to give informed consent in the geriatric ward were approached for study participation between May 2013 and December 2013. From these patients (who did not receive decolonization), swabs were also obtained on admission (T1) and on the fifth day after admission (T2). The inclusion of the control group on the geriatric ward was approved by the medical research ethics committee of the University Medical Center Utrecht (protocol number 13-036/C).
Microbiology
Nasal swabs were collected and inoculated onto selective agars, both with and without 8 mg/L mupirocin. Species determination was performed by MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) on all suspect growing colonies. Resistance to mupirocin in growing staphylococcal isolates was confirmed by Etest (bioMé rieux). The mupA gene was detected in staphylococcal isolates growing on the selective agars using a Lightcycler 480 II real-time PCR system (Roche Diagnostics, Mannheim, Germany). Multilocus variable tandem repeat analysis (MLVA) was used for the genotyping of Staphylococcus epidermidis as described in more detail elsewhere. 3 From each of the three wards, 25 consecutively isolated S. epidermidis strains from patients were typed. Further details on the microbiological testing, including the breakpoints used, can be found in the Supplementary data available at JAC Online.
Results
During the study period, 1578 surgical and 22 geriatric patients were screened on admittance, from whom in 936 (59%) surgical and 17 (77%) geriatric patients nasal swabs were obtained both at T1 and T2. Subsequent analysis was performed on the 936 surgical patients (930 unique patients and 6 readmissions) and 17 control patients with swabs taken at both T1 and T2. In surgical patients, mupirocin-resistant CoNS were detected at T1 and T2 in 192 (21%) and 406 (43%) patients, respectively (P, 0.001) ( Table 1) . Of the 744 patients not colonized at T1 and thus at risk of acquisition of mupirocin-resistant staphylococci, 277 (37%) acquired colonization at T2. This corresponds to an acquisition rate of 7.4/100 patient days at risk. Of the 192 patients colonized with mupirocin-resistant CoNS at T1, 129 (67%) were still colonized at T2 and 63 (33%) no longer had detectable colonization at T2. All 13 patients colonized at admittance with an intermediate resistant CoNS (MIC range 8 -256 mg/L) lost colonization by intermediate isolates at T2. Six of these 13 patients acquired a high-level resistant strain.
None of the 17 geriatric patients was colonized with mupirocinresistant CoNS at T1 or T2.
Overall, 607 mupirocin-resistant CoNS were identified in 469 patients, of which 588 (97%) had high-level resistance (MIC ≥512 mg/L). Almost all were S. epidermidis (568/607, 94%). Mupirocin-resistant S. aureus were not detected in 939 patients with swabs taken at T1 and T2. One patient carried a mupirocinresistant S. aureus (MIC 512 mg/L) at admission, with no swab taken at T2. Antibiotic susceptibility patterns besides mupirocin were determined in 100 randomly selected CoNS, revealing coresistance to oxacillin in 69%, aminoglycosides (either tobramycin or gentamicin resistance) in 61%, clindamycin in 61%, ciprofloxacin in 62%, trimethoprim/sulfamethoxazole in 51% and rifampicin in 8%.
A PCR for the detection of mupA was performed on 383/607 (63%) strains. mupA was detected in 381 of 383 strains (99.5%) high-level mupirocin-resistant CoNS and in four of 14 (29%) CoNS with intermediate resistance, with MICs ranging from 8 to 128 mg/L in mupA-positive strains. MLVA typing of 75 isolated high-level resistant S. epidermidis strains from the three surgery wards yielded 15 different genotypes, without a major dominant clone or evidence of clonal spread among those who acquired mupirocin-resistant S. epidermidis (Table S1 ).
Discussion
In this prospective cohort study, the prevalence of high-level resistance against mupirocin among CoNS was 21% before surgery and this increased to 43% after topical treatment with mupirocin and chlorhexidine body washing. Mupirocin-resistant S. aureus was only detected in one of 1578 patients at admission and no acquisition of mupirocin resistance was observed.
In this study, we screened for mupirocin-resistant staphylococci with an MIC ≥16 mg/L, thereby ignoring intermediate or low-level resistant isolates with MICs ,16 mg/L. Low-level mupirocin resistance in S. aureus is mediated through mutations in the native ileRS, whereas the plasmid-based mupA gene encodes high-level resistance. We focused on mupA-positive staphylococci because of the potential of this gene to spread between species in vitro and in vivo. 4, 5 Because 99.5% of the high-level resistant isolates harboured mupA, we did not look for the presence of mupB, an alternative gene encoding mupirocin resistance. 6 In addition to mupA, the qacA/B genes encoding resistance to antiseptics could potentially provide an additional source for crosstransmission between staphylococcal species and are commonly found in conjunction with low-level mupirocin resistance. 7 Clonal dissemination of mupirocin-resistant S. aureus and CoNS in hospital settings has been described. 8 Based on our MLVA typing, we were able to exclude the possibility that crosstransmission fuelled the acquisition during treatment. mupA has been detected in all major dominant MRSA clones, suggesting This study has several limitations. First, no broth enrichment was used, potentially underestimating the prevalence of S. aureus. Second, only a short period of follow-up was available for all patients, potentially underestimating the transfer rate of mupirocin resistance from CoNS to S. aureus. However, the universal decolonization strategy had already been implemented for almost a year on the cardiothoracic ward and only one mupirocin-resistant S. aureus was found. Third, no typing was performed on strains from patients colonized both at T1 and T2. Finally, as mupirocin-susceptible S. aureus and CoNS were not collected, we could not differentiate whether acquisition of mupirocin-resistant CoNS during decolonization resulted from resistance development of the colonizing strain, from selection of a pre-existent mupirocin-resistant strain under antibiotic pressure or from exogenous acquisition. We could also not assess the percentage of patients with nasal co-carriage of mupirocin-resistant CoNS and mupirocin-susceptible S. aureus at admission.
Transfer of mupA between S. epidermidis and S. aureus has been described during mupirocin prophylaxis in vitro and in vivo. 4 However, no mupirocin-resistant S. aureus were found at T2 during the study period, suggesting that horizontal transmission of the mupA gene from CoNS to S. aureus did not occur in ≥38 patients (assuming 20% of the patients are S. aureus carriers) carrying resistant CoNS at the start of treatment and with follow-up cultures obtained. Furthermore, no acquisition of mupirocin resistance in S. aureus was observed, which was in stark contrast to 37% of the patients acquiring mupirocin resistance in CoNS. The differences in acquisition rates between S. aureus and S. epidermidis are poorly understood and should be studied in future work.
Based on its beneficial cost-effectiveness profile, we recommend universal decolonization with mupirocin nasal ointment and chlorhexidine body washing. However, the pre-existing high prevalence and rapid increase of plasmid-based highlevel mupirocin resistance in CoNS during treatment warrant careful monitoring of mupirocin resistance development. In our study, horizontal gene transfer of mupA to S. aureus was not demonstrated in 936 patients during the 5 days of follow-up. Future studies determining the persistence of carriage with high-level mupirocin-resistant CoNS and quantifying the horizontal transfer rate in patients with longer follow-up are needed for more accurate assessment of the ecological safety of universal decolonization with mupirocin in surgical and critically ill patients.
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